Saxena A - Search Results

1

In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger.

Cerasoli DM, Griffiths EM, Doctor BP, Saxena A, Fedorko JM, Greig NH, Yu QS, Huang Y, Wilgus H, Karatzas CN, Koplovitz I, Lenz DE. Cerasoli DM, et al. Among authors: saxena a. Chem Biol Interact. 2005 Dec 15;157-158:363-5. doi: 10.1016/j.cbi.2005.10.052. Chem Biol Interact. 2005. PMID: 16429486

2

Immunochemical characterization of anti-acetylcholinesterase inhibitory monoclonal antibodies.

Gentry MK, Saxena A, Ashani Y, Doctor BP. Gentry MK, et al. Among authors: saxena a. Chem Biol Interact. 1993 Jun;87(1-3):227-31. doi: 10.1016/0009-2797(93)90046-2. Chem Biol Interact. 1993. PMID: 7688272

3

Characterization of monoclonal antibodies that inhibit the catalytic activity of acetylcholinesterases.

Gentry MK, Moorad DR, Hur RS, Saxena A, Ashani Y, Doctor BP. Gentry MK, et al. Among authors: saxena a. J Neurochem. 1995 Feb;64(2):842-9. doi: 10.1046/j.1471-4159.1995.64020842.x. J Neurochem. 1995. PMID: 7830078

4

Identification of amino acid residues involved in the binding of Huperzine A to cholinesterases.

Saxena A, Qian N, Kovach IM, Kozikowski AP, Pang YP, Vellom DC, Radić Z, Quinn D, Taylor P, Doctor BP. Saxena A, et al. Protein Sci. 1994 Oct;3(10):1770-8. doi: 10.1002/pro.5560031017. Protein Sci. 1994. PMID: 7849595 Free PMC article.

5

The role of glutamate-199 in the aging of cholinesterase.

Saxena A, Doctor BP, Maxwell DM, Lenz DE, Radic Z, Taylor P. Saxena A, et al. Biochem Biophys Res Commun. 1993 Nov 30;197(1):343-9. doi: 10.1006/bbrc.1993.2481. Biochem Biophys Res Commun. 1993. PMID: 7902714

6

Structure of glycan moieties responsible for the extended circulatory life time of fetal bovine serum acetylcholinesterase and equine serum butyrylcholinesterase.

Saxena A, Raveh L, Ashani Y, Doctor BP. Saxena A, et al. Biochemistry. 1997 Jun 17;36(24):7481-9. doi: 10.1021/bi963156d. Biochemistry. 1997. PMID: 9200697

7

Mutant acetylcholinesterases as potential detoxification agents for organophosphate poisoning.

Saxena A, Maxwell DM, Quinn DM, Radić Z, Taylor P, Doctor BP. Saxena A, et al. Biochem Pharmacol. 1997 Jul 15;54(2):269-74. doi: 10.1016/s0006-2952(97)00180-9. Biochem Pharmacol. 1997. PMID: 9271331

8

Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase.

Saxena A, Redman AM, Jiang X, Lockridge O, Doctor BP. Saxena A, et al. Biochemistry. 1997 Dec 2;36(48):14642-51. doi: 10.1021/bi971425+. Biochemistry. 1997. PMID: 9398183

9

Allosteric control of acetylcholinesterase activity by monoclonal antibodies.

Saxena A, Hur R, Doctor BP. Saxena A, et al. Biochemistry. 1998 Jan 6;37(1):145-54. doi: 10.1021/bi972061o. Biochemistry. 1998. PMID: 9425034

10

Role of oligosaccharides in the pharmacokinetics of tissue-derived and genetically engineered cholinesterases.

Saxena A, Ashani Y, Raveh L, Stevenson D, Patel T, Doctor BP. Saxena A, et al. Mol Pharmacol. 1998 Jan;53(1):112-22. doi: 10.1124/mol.53.1.112. Mol Pharmacol. 1998. PMID: 9443938

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,815 results

Search Page

Filters